Linzess is a brand name for the medication whose generic name is linaclotide [1][2].
What is Linzess used to treat?
Linzess is prescribed to treat adults with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) [1][3]. It works by increasing fluid secretion in the intestines, which helps to soften stool and promote bowel movements [3].
How does linaclotide work?
Linaclotide is a guanylate cyclase-C (GC-C) agonist [1]. By activating GC-C in the intestinal wall, it increases the secretion of chloride and bicarbonate into the intestinal lumen. This leads to increased fluid in the intestines, which softens stool and speeds up its transit time, thereby relieving constipation and abdominal pain associated with IBS-C and CIC [1][3].
When does the patent for Linzess expire?
The patent landscape for branded medications can be complex and involve multiple patents covering various aspects of the drug, including its formulation, method of use, and manufacturing process. Specific patent expiration dates can be found through resources like DrugPatentWatch.com [4]. Generally, brand-name drug patents offer market exclusivity for a defined period, after which generic versions may become available.
Can generic linaclotide be manufactured?
The potential for generic linaclotide depends on the expiration of relevant patents and any other regulatory exclusivity periods. Once these protections expire, and if regulatory approval is obtained, generic manufacturers can produce and market their versions of linaclotide [4].
Who makes linaclotide?
Linzess is manufactured by Ironwood Pharmaceuticals and AbbVie [2][5]. Ironwood Pharmaceuticals originally developed linaclotide.